SUTRO BIOPHARMA, INC. Defined Contribution Plan, Cost
SUTRO BIOPHARMA, INC. (STRO) reported Defined Contribution Plan, Cost of $200.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. defined contribution plan, cost for the quarter ending 2026-06-30 was $200.00K, a 33.33% decline year-over-year.
- SUTRO BIOPHARMA, INC. defined contribution plan, cost for the quarter ending 2026-03-31 was $200.00K, a 33.33% decline year-over-year.
- SUTRO BIOPHARMA, INC. defined contribution plan, cost for the quarter ending 2025-06-30 was $300.00K.
- SUTRO BIOPHARMA, INC. defined contribution plan, cost for the quarter ending 2025-03-31 was $300.00K.
- SUTRO BIOPHARMA, INC. defined contribution plan, cost for fiscal 2025 was $800.00K, a 46.67% decline from fiscal 2024.
- SUTRO BIOPHARMA, INC. defined contribution plan, cost for fiscal 2024 was $1.50M.
| Period end | Defined Contribution Plan, Cost 3 month | Defined Contribution Plan, Cost 6 month | Defined Contribution Plan, Cost 12 month |
|---|---|---|---|
| 2026-06-30 | $200.00K 10-Q · filed 2026-08-12 | $400.00K 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $200.00K 10-Q · filed 2026-05-14 | ||
| 2025-12-31 | $800.00K 10-K · filed 2026-03-23 | ||
| 2025-06-30 | $300.00K 10-Q · filed 2026-08-12 | $500.00K 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $300.00K 10-Q · filed 2026-05-14 | ||
| 2024-12-31 | $1.50M 10-K · filed 2026-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |